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Thermal Activation of Cardiac Thin Filaments Induces Contraction
without Intracellular Ca2D Changes: Studies with Cardiomyocytes and
an In Vitro Motility Assay
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It is well established that heart beat is triggered by electrical excitation, fol-
lowed by an increase in [Ca2þ]i and ensuing activation of myofilaments in car-
diomyocytes. This property is the basis for the regulation of the heart with
electric stimulators or chemical compounds that mediate Ca2þ signaling.
Recently, we found that microscopic heat pulses induce contractions in isolated
rat cardiomyocytes without a rise in [Ca2þ]i (Oyama, K. et al., Biochem. Bio-
phys. Res. Commun., 417, 607-612, 2012). Microscopic heat pulses produced
by focusing infrared laser beam increase temperature of the extracellular solu-
tion near cardiomyocytes. In our experiments, a microscopic heat pulse (DT =
5C for 0.5 sec) induced contractions at a basal temperature of 36C.When heat
pulses were repeatedly applied at 2.5 Hz, oscillatory contractions were
observed. In contrast to the electric field stimulation, Ca2þ transients were
not detected during the course of contraction. Moreover, we confirmed that
skinned cardiomyocytes are thermally activated in the Ca2þ-free solution. To
elucidate the molecular mechanism of thermal activation, microscopic heat
pulses were applied to an in vitro motility assay system utilizing reconstituted
thin filaments (rabbit skeletal actin filaments reconstituted with human cardiac
tropomyosin and bovine cardiac troponin). Thin filaments started to move dur-
ing heating in the absence of Ca2þ, and most of filaments immediately stopped
after switching the laser off, demonstrating that thin filaments can be thermally
activated, presumably due to the weakening of the binding affinity of the
troponin-tropomyosin complex with actin (Ishiwata, S., Biochim. Biophys.
Acta, 534, 350-357, 1978). These results suggest that heat pulses can regulate
cardiac contractions by shifting the ‘‘on-off’’ equilibrium in the thin filament
toward the ‘‘on’’ state, without accompanying intracellular Ca2þ transients.
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Faster Cross-Bridge Relaxation Rates Correlate with Increased Tension
Cost in Hcm with the R403Q Myh7 Mutation
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The first mutation found to be associated with hypertrophic cardiomyopathy
(HCM) is the R403Q mutation in the gene encoding b-myosin heavy chain.
R403Q is located in the globular head of myosin (S1), responsible for actin
interaction, and hence motor function of myosin. According to the 2-state
model of actin-myosin interaction total cross-bridge turnover rate can be
described by the sum of the cross-bridge association (fapp) and detachment
(gapp) rates. Gapp is equivalent to the slow rate of cross-bridge relaxation
(slow krel), which equals the energetic cost of tension generation, i.e. tension
cost (expressed by ATP utilization/tension). In the present study we investi-
gated to what extent cross-bridge kinetics in HCM with the R403Q mutation
correlated with cross-bridge energetics.
Left ventricular multicellular muscle strips and myofibrillar preparations were
isolated from 3 HCM patients with the R403Q mutation. 8 HCM sarcomere
mutation negative (HCMsmn) patients served as control. In the muscle strips
force generating capacity and ATP utilization were measured to assess tension
cost and in the myofibrillar preparations cross-bridge kinetics was analyzed.
The fraction of mutated R403Q mRNA was analyzed using specific restriction
digests and realtime-PCR. Compared to HCMsmn tension cost was higher in the
muscle strips of the 3 R403Q patients which showed a positive linear correla-
tion with relaxation kinetics in the corresponding myofibrillar preparations.
Variation in cross-bridge function among the 3 R403Q patients could not be
explained by differences in R403Q mRNA levels.
Cross-bridge cycling efficiency was decreased in HCM due to the R403Q mu-
tation, while cross-bridge kinetics was increased. This suggests that the
apparent gain in function evident from increased kinetics leads to a loss of func-tion with respect to cross-bridge cycling efficiency in HCM caused by the
R403Q mutation.
2837-Pos Board B529
The R403Q Mutation Alters Isometric and Energetic Properties in 2
Month Mice
Camille Birch, John Konhilas.
University of Arizona, Tucson, AZ, USA.
Introduction: Familial hypertrophic cardiomyopathy (FHC) is a primary disease
of the sarcomere. The R403Q mutation resides at the actin-interaction site on
myosin and leads to progressive hypertrophic cardiomyopathy that can result
in sudden cardiac death or congestive heart failure. Previous studies examining
the functional impact of the R403Q mutation give inconsistent results such as
either reduced or enhanced actin-activated ATPase. We hypothesized that the
R403Q mutation intrinsically increases the energetic cost of contraction.
Methods: To do this, we assessed Ca2þ-sensitivity of tension and cross-bridge
kinetics in de-membranated cardiac trabeculae from wild-type (WT) and
R403Q hearts at 2 months of age. Assuming a two-state model of cross-
bridge binding and un-binding, we measured cross-bridge kinetics using 2
methods: (1) the rate of ATP hydrolysis (off-rate) by NADH oxidation that
is enzymatically and stoichiometrically coupled to ATP consumption, and
(2) the rate of force redevelopment (ktr; on-rate plus off-rate) by a rapid
release-restretch protocol.
Results: Male R403Q mice display a decrease in Ca2þ sensitivity (2.461mM5
0.072) compared to WT males and females (2.189 mM 5 0.059 and
2.166 mM50.044, respectively) at SL 2.0mm. R403Q males display increased
tension cost at SL 2.0mmwhen compared to WT counterparts (9.565 0.68 and
6.82 51.07 pmol s-1 mm-1 mN-1, respectively). At maximal activation, the
rate of force redevelopment (ktr) is not significantly different between
R403Q and WT males (40.2656.86 and 30.2653.95 s-1).
Conclusions: Although maximal ktr is not significantly different between WT
and R403Q males, an increase in ATP hydrolysis (off rate) suggests an alter-
ation in cross-bridge kinetics. Importantly, future studies will explore the rela-
tionship between submaximal activation and ktr. Along with no overt
pathology at 2 months, the R403Q mutation alters the energetic cost of contrac-
tion and isometric properties.
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The Hcm Mutation R453C in the Human Beta Myosin Motor Domain
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The human hypertrophic cardiomyopathy mutation R453C is associated with a
high incidence of sudden cardiac death. We have expressed the motor domain
(MD) of human beta-myosin and the human ventricular essential light chain
(MLC3) with the R453C mutation using a mouse muscle cell line. We have
examined the binding of nucleotides to the MD and actin$MD and compared
the kinetic data to our previous study of the wild type MD (Deacon et al
2012). Little change was observed in the binding of ATP or ADP to actin$MD
but the two fluorescence changes accompanying ATP binding to MD in the
absence of actin were slower. The fast phase, previously assigned to the
conformational change accompanying tight binding of ATP to the motor,
was slowed by 30%. The slow phase,assigned to the closure of switch 2
and the recovery stroke, associated with the ATP hydrolysis step, were slowed
~ 3 fold. The R453C mutation is located in a surface loop that links the
switch-2 beta strand with the long O-helix that connects to the cardiomyopa-
thy loop in the actin binding site. R453C is therefore in a position to influence
both actin binding and switch 2 closure. The surface loop and R453 are
conserved only in sarcomeric myosins, suggesting a specific role for the
loop in muscle. Supported by NIH grants GM29090 and GM65013 and Well-
come Trust grant 085309.
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Spectroscopic System for Characterization of Human b-Cardiac Myosin
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We designed a system to examine the structural properties of human b-cardiac
myosin using fluorescence spectroscopy. Expression of human b-cardiac
562a Tuesday, February 18, 2014myosin subfragment 1 (M2B-S1) was achieved through the generation of re-
combinant adenovirus with subsequent infection in the C2C12 embryonic mus-
cle cell line. A tetracysteine site, which enables site-specific labeling of the
fluorescein biarscenical hairpin-binding dye (FlAsH), was introduced in the up-
per 50 kDa (U50) region (residues 316-321) corresponding to the previously
utilized site in myosin V. Key conformational changes in the myosin motor,
including those associated with nucleotide and actin binding, can be examined
by fluorescence resonance energy transfer (FRET) using M2B-S1 FlAsH and
fluorescent nucleotides or IAEDANs-labeled actin. We demonstrate the enzy-
matic properties of M2B-S1 FlAsH are similar to unlabeled M2B-S1, and both
are capable of moving actin filaments in the in vitromotility assay. We utilized
FRET between M2B-S1 FlAsH and Cy3ATP to examine structural changes in
the U50 domain. The kinetics of structural changes were examined during the
ATP-binding and actin-activated product release steps. We also designed a sys-
tem to study structural changes in the force-generating lever arm using FlAsH
labeling at the N-terminus of a human b-cardiac myosin construct containing a
C-terminal GFP (M2B-GFP). The spectroscopic approach can be used as a tool
to study the effects of hypertrophic cardiomyopathy (HCM) mutations on
myosin structure or to study the impact of drugs that alter myosin motor
activity.
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Differences in Activation and Relaxation Kinetics of Human Fetal Skeletal
and Cardiac Myofibrils
Alice Ward Racca1, Anita E. Beck2, Michael J. Bamshad2,
Michael Regnier1.
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Embryonic (MYH3), perinatal (MYH8), and alpha (MYH6) myosin heavy
chains are predominantly expressed during prenatal development of human
skeletal and cardiac muscle and may be upregulated following injury. To
determine how mutations in these genes affect performance, development,
and injury recovery, it is important to understand the contractile properties
of the human fetal muscle in which these isoforms are dominant. However,
information on developing human skeletal and cardiac muscle is limited.
We previously reported that human fetal skeletal muscle from a single fetus
of ~16 weeks gestation had slower crossbridge cycling myosin compared to
adult rabbit psoas myosin (in vitro motility measurements) and slower myofi-
bril activation & relaxation kinetics accompanying weaker force production
than adult human skeletal myofibrils (Racca et al. (2013) J.Phys 591:3049-
3061). Here we characterized and compared the contraction and relaxation
properties of human fetal skeletal (HFS) and cardiac (HFC) muscle from
fetuses of ~16 weeks gestation using myofibril mechanics techniques.
HFC muscle was isolated and used fresh, while HFS muscle was flash-
frozen in liquid nitrogen prior to use. The HFC myosin propelled unregulated
F-actin filaments 49% slower than HFS myosin (HFC:1.6650.13mm$s1;
HFS:2.6450.02mm$s1) (2mM ATP, 30C). During maximal calcium
activation (15C), HFC myofibrils produced more force (FMAX=
10.553.6mN/mm2) than HFS (5.951.2mN/mm2), at slightly slower rates
(HFC:kACT=0.4650.09s
1; HFS:0.6650.10s1). The initial (slow) phase of
relaxation was slightly longer in duration (HFC:tREL,slow=203527ms;
HFS:174513ms), and slower in slope (HFC:kREL,slow=0.2650.03s
1;
HFS:0.5950.15s1), indicating slower crossbridge release which may also be
influenced by troponin regulation. The secondary (fast) phase of relaxation
was similar (HFC:kREL,fast=1.850.2s
1;HFS:1.550.2s1). Research to charac-
terize the contractile properties of early development muscle and myosin heavy
chain isoforms is ongoing, and may elucidate their role in development and
muscle repair. Supported by F31AR06300(A.R.), 5K23HD057331(A.B.),
HD048895(M.B.,M.R.).
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Improved Loaded In Vitro Motility Assay and Actin Filament Tracking
Software Delineates the Effect of Hypertrophic and Dilated Cardiomyop-
athy Mutations on the Power Output of Cardiac Myosin
Tural Aksel, Masataka Kawana, Arjun Adhikari, Shirley Sutton,
Kathleen Ruppel, James Spudich.
Biochemistry, Stanford University, Stanford, CA, USA.
Hypertrophic (HCM) and dilated (DCM) cardiomyopathies are important
causes of heart failure, arrhythmia, and sudden cardiac death. HCM is the
most common heritable cardiovascular disorder, affecting 1 in 500 individ-
uals, and is caused primarily by mutations that alter proteins of the cardiac
sarcomere. Sarcomeric protein mutations are an increasingly recognized cause
of familial DCM as well. HCM is associated with severe thickening of the leftventricular wall, preserved/increased systolic (contractile) and impaired dia-
stolic (relaxation) function of the heart. DCM hearts have dilated left ventric-
ular chambers and suffer from inadequate systolic activity. More than 300
point mutations in beta-cardiac myosin are associated with HCM or DCM.
It is believed that HCM and DCM mutations increase and decrease respec-
tively the power output of cardiac myosin which leads to a cascade of down-
stream signaling that gradually leads to the disease phenotype. To test this
hypothesis it is essential to measure the power output of all HCM/DCM mu-
tants in a high throughput manner. To quantitatively measure the load depen-
dent myosin power output, we first improved the loaded in vitro motility assay
(LIMA) by replacing load generating molecule alpha-actinin with alpha-
catenin, which was generously provided by James Nelson at Stanford Univer-
sity. For accurate-and-fast data analysis, we developed a software called
FAST that runs over parallel CPUs. Our initial results indicate that two
HCM mutants (R719W, R403Q) have higher power output than the wildtype
cardiac myosin. FAST-LIMA will be an essential tool for screening drugs that
revert the effects of HCM/DCMmutations on the power output of beta-cardiac
myosin.
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Modulation of the Cardiac Sarcomere by a Small Molecule Agent
MYK0000461: A Potential Therapeutic for the Treatment of Genetic Hy-
pertrophic Cardiomyopathies
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1Biology, MyoKardia, Inc., South San Francisco, CA, USA, 2Chemistry,
MyoKardia, Inc., South San Francisco, CA, USA.
We have identified a small molecule inhibitor, MYK0000461, of the cardiac
myosin ATPase. This agent was characterized in steady state and transient ki-
netic assays to understand its mechanism of action. MYK0000461 decreases
the steady-state rate of the ATPase activity of purified bovine b-cardiac myosin
subfragment-1 (S1) as well as that of bovine cardiac myofibrils, wild type and
the mutant R453C of recombinant human b-cardiac myosin S1. We also find
that MYK0000461 inhibits cardiac myosin selectively as compared to systems
containing rabbit skeletal or chicken smooth muscle myosins Analysis of the
individual steps of the chemo-mechanical cycle of cardiac myosin suggests
that MYK0000461 exerts its effect by inhibiting the actin-stimulated release
of phosphate, presumably by stabilizing the detached state of cardiac myosin
prior to the release of phosphate. We find no evidence to suggest that
MYK000461 inhibits cardiac myosin in a strongly bound state and no other
steps in the chemo-mechanical cycle are affected by MYK0000461. Thus,
the enzymatic step governing the weak to strong transition of S1 binding to
actin is inhibited without affecting the release from the strongly bound states.
This decrease in the rate of transition from the weak to strongly bound state
should decrease force production and may underlie its ability to decrease car-
diac contractility in cellular and in vivo models of cardiac function. An agent
such as MYK0000461 could potentially be used to treat cardiac disorders
that stem from hyper contractility such as the genetic hypertrophic cardiomy-
opathies (HCM). By decreasing the net force of contraction and restoring it
back to normal level could potentially be useful in treating patients that suffer
from this disease.
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Biophysical Analysis of the Putative Heart Failure Drug Omecamtiv
Mecarbil
Joseph M. Muretta, Ewa Prochniewicz, David D. Thomas.
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The small molecule omecamtiv mecarbil (OM), currently in late phase-2 clin-
ical trials for treatment of heart failure, activates force generation by cardiac
myosin. How OM increases force generation is not known. Crosslinking and
molecular docking studies suggest that the compound binds to the relay/SH1/
converter region of myosin, hypothesized to control the actin-activated pre to
post power-stroke structural transition in the myosin catalytic and light-chain
domains. These transitions drive force production by myosin. We are currently
using time-resolved FRET and EPR distance measurements to detect the pre-
and post-power-stroke structural states of myosin. We have performed these
studies on tissue-purified b-cardiac and a-skeletal myosin, and on a recombi-
nant cys-lite myosin II catalytic domain model from Dictyostelium discoideum.
In each of the myosin isoforms, we find that OM binding increases the mole
fraction of the myosin post power-stroke structural state in the presence of
ATP analogs. Transient time-resolved FRET experiments, mixing FRET-
labeled myosin with ATP, show that drug binding also alters the structural ki-
netics of the myosin recovery-stroke. Ongoing studies are investigating the
